Skip to Content

Actemra Approval History

Actemra (tocilizumab) is a humanized interleukin-6 (IL-6) receptor-inhibiting monoclonal antibody for the treatment rheumatoid arthritis; systemic juvenile idiopathic arthritis (SJIA); polyarticular juvenile idiopathic arthritis (PJIA); giant cell arteritis; and CAR T cell-induced severe or life-threatening cytokine release syndrome.

Development History and FDA Approval Process for Actemra

May 14, 2018Approval FDA Approves Subcutaneous Formulation of Actemra for use in Active Polyarticular Juvenile Idiopathic Arthritis
Aug 31, 2017Approval FDA Approves Genentech’s Actemra (tocilizumab) for the Treatment of CAR T Cell-Induced Cytokine Release Syndrome
May 22, 2017Approval FDA Approves Actemra (tocilizumab) Subcutaneous Injection for Giant Cell Arteritis
Oct 22, 2013Approval Genentech Gains FDA Approval for New Subcutaneous Formulation of Actemra for use in Adult Patients Living with Moderately to Severely Active Rheumatoid Arthritis
Apr 30, 2013Approval FDA Approves Actemra for Children with Polyarticular Juvenile Idiopathic Arthritis
Apr 17, 2011Approval FDA Approves Actemra (tocilizumab) for the Treatment of Systemic Juvenile Idiopathic Arthritis (SJIA)
Jan  5, 2011Approval FDA Grants Supplemental Approval for Actemra (tocilizumab)
Jan 11, 2010Approval FDA Approves Actemra for the Treatment of Moderately to Severely Active Rheumatoid Arthritis
Dec  4, 2008Roche and FDA Agree on Pathway Towards U.S. Approval of Actemra (tocilizumab)
Sep 18, 2008FDA Issues Complete Response Letter to Roche for Acterma (tocilizumab) Biologics License Application
Jul 29, 2008FDA Advisory Committee Recommends Approval of Actemra (tocilizumab) for the Treatment of Rheumatoid Arthritis
Nov 21, 2007Roche Submits Application for FDA Approval of Actemra for theTreatment of Rheumatoid Arthritis

Disclaimer: Every effort has been made to ensure that the information provided here is accurate, up-to-date and complete, but no guarantee is made to that effect. Drug information contained herein may be time sensitive. This information has been compiled for use by healthcare practitioners and consumers in the United States. The absence of a warning for a given drug or combination thereof in no way should be construed to indicate that the drug or combination is safe, effective or appropriate for any given patient. If you have questions about the substances you are taking, check with your doctor, nurse or pharmacist.